Main View
This view is used for searching all possible sources.
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
1
Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering.
2010-08-16

Soluble oligomeric aggregates of the amyloid-beta peptide (Abeta) have been implicated in the pathogenesis of Alzheimer's disease (AD). Although the conformation adopted by Abeta within these aggregates is not known, a beta-hairpin conformation is known to be accessible to monomeric Abeta. Here we show that this ...

PubMed

2
Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.
2009-02-01

Small beta-amyloid (Abeta) 1-42 aggregates are toxic to neurons and may be the primary toxic species in Alzheimer's disease (AD). Methods to reduce the level of Abeta, prevent Abeta aggregation, and eliminate existing Abeta aggregates have been proposed for treatment of AD. A tricyclic pyrone named CP2 is found to ...

PubMed

3
Pin1 affects Tau phosphorylation in response to Abeta oligomers.
2009-06-09

We show that in hippocampal cultured neurons, dephosphorylation of peptidyl-prolyl cis-trans isomerase Pin1 on Ser16 is occurring during the early stages of exposure to Abeta (1-42) oligomers. This occurrence, resulting in Pin1 activation, is paralleled by Tau(Thr231) dephosphorylation, probably due to Pin1-mediated Tau isomerisation. ...

PubMed

4
A glycine zipper motif mediates the formation of toxic beta-amyloid oligomers in vitro and in vivo.
2011-08-23

ABSTRACT: BACKGROUND: The beta-amyloid peptide (Abeta) contains a Gly-XXX-Gly-XXX-Gly motif in its C-terminal region that has been proposed to form a "glycine zipper" that drives the formation of toxic Abeta oligomers. We have tested this hypothesis by examining the toxicity of Abeta variants containing ...

PubMed

5
Therapeutics for Alzheimer's disease based on the metal hypothesis.
2008-07-01

Alzheimer's disease is the most common form of dementia in the elderly, and it is characterized by elevated brain iron levels and accumulation of copper and zinc in cerebral beta-amyloid deposits (e.g., senile plaques). Both ionic zinc and copper are able to accelerate the aggregation of Abeta, the principle component of beta-amyloid deposits. Copper (and iron) can also ...

PubMed

6
Monoclonal antibodies that target pathological assemblies of Abeta.
2006-11-20

Amyloid beta (Abeta) immunotherapy for Alzheimer's disease has shown initial success in mouse models of Alzheimer's disease and in human patients. However, because of meningoencephalitis in clinical trials of active vaccination, approaches using therapeutic antibodies may be preferred. As a novel antigen to generate monoclonal antibodies, the current study has used ...

PubMed

7
Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification.
2009-01-06

ABSTRACT: BACKGROUND: The amyloid beta-peptide is a ubiquitous peptide, which is prone to aggregate forming soluble toxic oligomers and insoluble less-toxic aggregates. The intrinsic and external/environmental factors that determine Abeta aggregation in vivo are poorly understood, as well as the cellular meaning of this process itself. Genetic data as well ...

PubMed

8
Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo.
2010-03-16

Protein aggregation, arising from the failure of the cell to regulate the synthesis or degradation of aggregation-prone proteins, underlies many neurodegenerative disorders. However, the balance between the synthesis, clearance, and assembly of misfolded proteins into neurotoxic aggregates remains poorly understood. Here we study the effects of modulating this balance for the amyloid-beta ...

PubMed

9
Effect of transition metals in synaptic damage induced by amyloid beta peptide.
2010-07-29

The amyloid beta-peptide (Abeta), which is thought to be the major cause of Alzheimer's disease (AD), is known to be capable of aggregating in different states: soluble monomers and oligomers, and insoluble aggregates. The Abeta aggregation state as well as its toxicity has been related to the interaction between the peptide and ...

PubMed

10
Association thermodynamics and conformational stability of beta-sheet amyloid beta(17-42) oligomers: effects of E22Q (Dutch) mutation and charge neutralization.
2010-01-20

Amyloid fibrils are associated with many neurodegenerative diseases. It was found that amyloidogenic oligomers, not mature fibrils, are neurotoxic agents related to these diseases. Molecular mechanisms of infectivity, pathways of aggregation, and molecular structure of these oligomers remain elusive. Here, we use all-atom molecular dynamics, molecular ...

PubMed

11
Alzheimer's-associated A{beta} oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal
2009-10-15

It now appears likely that soluble oligomers of amyloid-{beta}{sub 1-42} peptide, rather than insoluble fibrils, act as the primary neurotoxin in Alzheimer's disease (AD). Consequently, compounds capable of altering the assembly state of these oligomers (referred to as ADDLs) may have potential for AD therapeutics. Phenolic compounds are of ...

Energy Citations Database

12
Template-directed deposition of amyloid
2006-01-01

The formation of amyloid plaques in tissue is a pathological feature of many neurodegenerative diseases. Amyloid deposition, the process of amyloid plaque growth by the association of individual soluble amyloid molecules with a pre-existing amyloid template (i.e. plaque), is known to be critical for amyloid formation in vivo. In order to characterize amyloid deposition, we developed novel, ...

NASA Astrophysics Data System (ADS)

13
Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons.
2010-07-01

Disruption of axonal transport is a hallmark of several neurodegenerative diseases, including Alzheimer's disease (AD). Even though defective transport is considered an early pathologic event, the mechanisms by which neurodegenerative insults impact transport are poorly understood. We show that soluble oligomers of the amyloid-beta peptide ...

PubMed

14
Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly.
2009-08-05

Soluble oligomeric amyloid-beta (Abeta) species are toxic to many cell types and are a putative etiological factor in Alzheimer's disease. The NINDS-Custom Collection of 1040 drugs and biologically active compounds was robotically screened for inhibitors of Abeta oligomer formation with a single-site biotinylated ...

PubMed

15
Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.
2009-07-15

Both insulin resistance (type II diabetes) and beta-amyloid (Abeta) oligomers are implicated in Alzheimer's disease (AD). Here, we investigate the role of Abeta oligomer-induced c-Jun N-terminal kinase (JNK) activation leading to phosphorylation and degradation of the adaptor protein insulin receptor substrate-1 ...

PubMed

16
Alzheimer's Abeta fused to green fluorescent protein induces growth stress and a heat shock response.
2007-07-27

The 42 amino acid Alzheimer's Abeta peptide is involved in the progression of Alzheimer's disease. Here we describe the effects of intracellular Abeta, produced through its attachment to either end of a green fluorescent protein, in yeast. Cells producing Abeta exhibited a lower growth yield and a heat shock response, ...

PubMed

17
Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.
2004-08-20

A new concept is introduced for the rational design of beta-sheet ligands, which prevent protein aggregation. Oligomeric acylated aminopyrazoles with a donor-acceptor-donor (DAD) hydrogen bond pattern complementary to that of a beta-sheet efficiently block the solvent-exposed beta-sheet portions in Abeta-(1-40) and thereby prevent formation of insoluble protein aggregates. ...

PubMed

18
Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.
2010-05-19

High-fat diet and certain dietary patterns are associated with higher incidence of sporadic Alzheimer's disease (AD) and cognitive decline. However, no specific therapy has been suggested to ameliorate the negative effects of high fat/high cholesterol levels on cognition and amyloid pathology. Here we show that in 9-month-old APP23 mice, a high-fat/high-cholesterol (HF) diet ...

PubMed

19
Amyloid Beta Causing Forgetfulness
2009-04-14

Professor Dennis Selkoe discusses an experiment by his group which found that a-beta oligomers temporarily injected into rat's brains caused temporary forgetfulness.

NSDL National Science Digital Library

20
Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses.
2009-08-21

Molecular probes for selective identification of protein aggregates are important to advance our understanding of the molecular pathogenesis underlying cerebral amyloidoses. Here we report the chemical design of pentameric thiophene derivatives, denoted luminescent conjugated oligothiophenes (LCOs), which could be used for real-time visualization of cerebral protein aggregates in transgenic mouse ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
21
Membrane charge dependent states of the beta-amyloid fragment Abeta (16-35) with differently charged micelle aggregates.
2010-01-04

Abeta (16-35) is the hydrophobic central core of beta-amyloid peptide, the main component of plaques found in the brain tissue of Alzheimer's disease patients. Depending on the conditions present, beta-amyloid peptides undergo a conformational transition from random coil or alpha-helical monomers, to highly toxic beta-sheet oligomers and aggregate fibrils. ...

PubMed

22
Insulin Promotes Survival of Amyloid-Beta Oligomers Neuroblastoma Damaged Cells via Caspase 9 Inhibition and Hsp70 Upregulation
2010-05-13

Alzheimer's disease (AD) and type 2 diabetes are connected in a way that is still not completely understood, but insulin resistance has been implicated as a risk factor for developing AD. Here we show an evidence that insulin is capable of reducing cytotoxicity induced by Amyloid-beta peptides (A-beta) in its oligomeric form in a dose-dependent manner. By ...

PubMed Central

23
Two disaccharides and trimethylamine N-oxide affect Abeta aggregation differently, but all attenuate oligomer-induced membrane permeability.
2009-09-22

Interaction between aggregates of amyloid beta protein (Abeta) and membranes has been hypothesized by many to be a key event in the mechanism of neurotoxicity associated with Alzheimer's disease (AD). Proposed membrane-related mechanisms of neurotoxicity include ion channel formation, membrane disruption, changes in membrane capacitance, and lipid membrane oxidation. Recently, ...

PubMed

24
Expression and purification of amyloid-beta peptides from Escherichia coli.
2009-02-20

Soluble oligomers and fibrillar deposits of amyloid beta (Abeta) are key agents of Alzheimer's disease pathogenesis. However, the mechanism of amyloid aggregation and its interaction with live cells still remain unclear requiring the preparation of large amounts of pure and different Abeta peptides. Here we describe an Escherichia coli ...

PubMed

25
No correlation between time-linked plasma and CSF Abeta levels.
2009-08-18

Plasma beta-amyloid protein (Abeta) isoforms are considered potential biomarkers for Alzheimer's disease (AD) and dementia. The relation between plasma and cerebrospinal fluid (CSF) levels of Abeta isoforms remains unclear. In order to identify possible correlations between Abeta levels in plasma and CSF we determined ...

PubMed

26
Structure-neurotoxicity relationships of amyloid beta-protein oligomers.
2009-08-12

Amyloid beta-protein (Abeta) oligomers may be the proximate neurotoxins in Alzheimer's disease (AD). "Oligomer" is an ill-defined term because many kinds have been reported and they often exist in rapid equilibrium with monomers and higher-order assemblies. We report here results of studies in which specific ...

PubMed

27
Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
2006-06-01

Senile plaques (SPs), one of two defining lesions of Alzheimer's disease (AD), are composed of a mixture of full-length Abeta1-40/42, and N- or C-terminally truncated Abeta peptides, including Abeta11-40/42. Sequential proteolysis of amyloid precursor protein (APP) by beta- and gamma-secretases produces ...

PubMed

28
Is the viscoelasticity of Alzheimer's Abeta42 peptide oligomers a general property of protein oligomers related to their toxicity?
2010-07-20

The largest group of protein misfolding diseases is associated with the conversion of specific peptides or proteins from their soluble functional states into highly organized fibrillar aggregates named amyloid fibrils or plaques. The amyloid-beta peptide (Abeta) is involved in pathogenesis of Alzheimer's disease (AD), being the main constituent of the amyloid plaques found in ...

PubMed

29
Conversion of non-fibrillar {beta}-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation
2007-10-05

A{beta}(1-40) is one of the main components of the fibrils found in amyloid plaques, a hallmark of brains affected by Alzheimer's disease. It is known that prior to the formation of amyloid fibrils in which the peptide adopts a well-ordered intermolecular {beta}-sheet structure, peptide monomers associate forming low and high molecular weight ...

Energy Citations Database

30
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.
2008-02-17

During the last 25 years, neuropathological, biochemical, genetic, cell biological and even therapeutic studies in humans have all supported the hypothesis that the gradual cerebral accumulation of soluble and insoluble assemblies of the amyloid beta-protein (Abeta) in limbic and association cortices triggers a cascade of biochemical and cellular alterations that produce the ...

PubMed

31
Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation.
2008-06-26

scyllo-Inositol has shown promise as a potential therapeutic for Alzheimer's disease, by directly interacting with the amyloid beta (Abeta) peptide to inhibit Abeta42 fiber formation. To explore the molecular details of the inositol-Abeta42 interaction, a series of scyllo-inositol derivatives have been synthesized which contain deoxy, ...

PubMed

32
Cells - a-beta inhibits long-term potentiation
2009-12-26

Professor Dennis Selkoe notes amyloid beta oligomers are very potent inhibitors of long-term potentiation (LTP) and can 'short circuit' synapses in the hippocampus.

NSDL National Science Digital Library

33
The interaction of amyloid Abeta(1-40) with lipid bilayers and ganglioside as studied by 31P solid-state NMR.
2008-12-24

Amyloid beta-peptide (Abeta) is a major component of plaques in Alzheimer's disease, and formation of senile plaques has been suggested to originate from regions of neuronal membrane rich in gangliosides. We analyzed the mode of interaction of Abeta with lipid bilayers by multinuclear NMR using (31)P nuclei. We found that Abeta (1-40) ...

PubMed

34
Monitoring the earliest amyloid-beta oligomers via quantized photobleaching of dye-labeled peptides.
2008-07-19

Misfolding and aggregation of amyloid-beta peptide (Abeta) are widely recognized as causative events in Alzheimer's disease (AD). Contrary to earlier hypotheses, recent studies have identified soluble Abeta oligomers as the pathogenic agents and documented neurodegenerative effects from species as small as dimers and trimers. As such, ...

PubMed

35
Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate.
2007-10-02

Alzheimer's disease (AD) is characterized by large numbers of senile plaques in the brain that consist of fibrillar aggregates of 40- and 42-residue amyloid-beta (Abeta) peptides. However, the degree of dementia in AD correlates better with the concentration of soluble Abeta species assayed biochemically than with histologically determined plaque counts, ...

PubMed

36
Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model.
2009-09-08

Amyloid plaque deposition in the brain is a hallmark of Alzheimer's disease, but recent evidence indicates that the disease may be primarily caused by soluble amyloid-beta (1-42) (Abeta) oligomers or Abeta-derived diffusible ligands (ADDLs). ADDLs induce cognitive deficits in animal models and are thought to assemble in vitro by a ...

PubMed

37
Structures of Abeta-related peptide--monoclonal antibody complexes.
2009-06-16

Passive immunotherapy (PI) is being explored as a potential therapeutic against Alzheimer's disease. The most promising antibodies (Abs) used in PI target the EFRH motif of the Abeta N-terminus. The monoclonal anti-Abeta Ab PFA1 recognizes the EFRH epitope of Abeta. PFA1 has a high affinity for Abeta fibrils and ...

PubMed

38
Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
2002-01-01

Deregulation of amyloid precursor protein (APP) processing with increased production of amyloid beta-peptide (Abeta) is considered to be a key pathogenic event in Alzheimer's disease (AD). It has been suggested that stimulation of the muscarinic M(1) receptor subtype affects APP processing and leads to a change in Abeta concentration. To test the ...

PubMed

39
Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.
2009-08-19

Radiolabeled Pittsburgh compound B (PIB) is a benzothiazole imaging agent that usually binds with high affinity, specificity, and stoichiometry to cerebral beta-amyloid (Abeta) in patients with Alzheimer's disease. Among a cohort of ten AD subjects examined postmortem, we describe a case of idiopathic, end-stage Alzheimer's disease with heavy Abeta ...

PubMed

40
Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease.
2010-01-18

The presence of amyloid-beta (Abeta) deposits in selected brain regions is a hallmark of Alzheimer's disease (AD). The amyloid deposits have "chaperone molecules" which play critical roles in amyloid formation and toxicity. We report here that treatment of rat hippocampal neurons with Abeta-acetylcholinesterase (Abeta-AChE) complexes ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
41
Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assemblies.
2004-06-01

Amyloidoses comprise a class of diseases characterized pathologically by the presence of deposits of fibrillar, aberrantly folded proteins, known as amyloids. Historically, these deposits were considered the key factors causing disease. However, recent evidence suggests that soluble protein oligomers, which are precursors for amyloid fibrils, are the primary toxic effectors ...

PubMed

42
{beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution.
2009-02-24

A fundamental feature of Alzheimer disease (AD) is the accumulation of beta-amyloid (Abeta), a peptide generated from the amyloid precursor protein (APP). Emerging evidence suggests that soluble Abeta oligomers adversely affect synaptic function, which leads to cognitive failure associated with AD. The ...

PubMed

43
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.
2005-12-22

Aggregation of the amyloid-beta (Abeta) peptide in the extracellular space of the brain is central to Alzheimer's disease pathogenesis. Abeta aggregation is concentration dependent and brain region specific. Utilizing in vivo microdialysis concurrently with field potential recordings, we demonstrate that Abeta levels in the brain ...

PubMed

44
Alzheimer Abeta(1-42) monomer adsorbed on the self-assembled monolayers.
2010-08-01

Amyloid-beta (Abeta) peptide aggregation on the cell membranes is a key pathological event responsible for neuron cell death in Alzheimer's disease (AD). We present a collection of molecular docking and molecular dynamics simulations to study the conformational dynamics and adsorption behavior of Abeta monomer on the self-assembled monolayer (SAM), in ...

PubMed

45
Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.
2008-01-01

A transgenic mouse bearing mutant transgenes linked to familial forms of Alzheimer's disease (AD) for the amyloid precursor protein and presenilin-1 (TASTPM) showed Abeta plaque deposition and age-related histological changes in associated brain pathology. The Abeta present was of multiple forms, including species with a C-terminus at ...

PubMed

46
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.
2007-02-16

Oxidative stress is a major aspect of Alzheimer disease (AD) pathology. We have investigated the relationship between oxidative stress and neuronal binding of Abeta oligomers (also known as ADDLs). ADDLs are known to accumulate in brain tissue of AD patients and are considered centrally related to pathogenesis. Using hippocampal neuronal cultures, we found ...

PubMed

47
Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors.
2006-05-11

In vitro testing for inhibitors of oligomer formation of pathologically misfolded proteins such as Alzheimer's beta-peptide (Abeta) has been limited by the lack of a suitably sensitive high-throughput method for measuring oligomers. Even with the development of oligomer-specific antibodies and a single-site ...

PubMed

48
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.
2007-01-24

The basis for memory loss in early Alzheimer's disease (AD) seems likely to involve synaptic damage caused by soluble Abeta-derived oligomers (ADDLs). ADDLs have been shown to build up in the brain and CSF of AD patients and are known to interfere with mechanisms of synaptic plasticity, acting as gain-of-function ligands that attach to synapses. Because of ...

PubMed

49
Clearance of amyloid-beta peptide by neuronal and non-neuronal cells: proteolytic degradation by secreted and membrane associated proteases.
2007-11-01

Deposition of amyloid-beta peptide (Abeta) in the brain is an early and invariant feature of all forms of Alzheimer's disease (AD). As for all proteins or peptides, the steady-state level of Abeta peptide is determined not only by its production, but also by its degradation. So, overactive proteases involved in generating Abeta from ...

PubMed

50
Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide.
2009-11-12

One of the neuropathological hallmarks of Alzheimer's disease (AD) is the amyloid plaque, primarily composed of aggregated amyloid-beta (Abeta) peptide. In vitro, Abeta(1-42), the major alloform of Abeta found in plaques, self-assembles into fibrils at micromolar concentrations and acidic pH. Such conditions do not exist in the ...

PubMed

51
Chapter 6 The static polarizability of oligomers

Chapter 6 The static polarizability of oligomers In this chapter we show our results for the static polarizability of oligomers of several polymeric systems. The systems we study in this chapter are the model that are nonconjugated (polyethylene and the model hydrogen chain), -conjugated (polysilane), or -conjugated ...

E-print Network

52
Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease.
2007-02-01

Abnormal accumulation of neurotoxic beta-amyloid peptides (Abeta) in brain represents a key factor in the progression of Alzheimer's disease (AD). Identification of small molecules that effectively reduce brain levels of Abeta is important for development of Abeta-lowering agents for AD. In this study, we demonstrate that in vivo ...

PubMed

53
Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.
2008-12-01

The rat amyloid-beta (Abeta) intracerebroventricular infusion can model aspects of Alzheimer's disease (AD) and has predicted efficacy of therapies such as ibuprofen and curcumin in transgenic mouse models. High density lipoprotein (HDL), a normal plasma carrier of Abeta, is used to attenuate Abeta aggregation within the pump, causing ...

PubMed

54
"Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization.
2010-08-26

In our effort to develop multifunctional compounds that cotarget beta-amyloid oligomers (AbetaOs), cell membrane/lipid rafts (CM/LR), and oxidative stress, a series of bivalent multifunctional Abeta oligomerization inhibitors (BMAOIs) containing cholesterol and curcumin were designed, synthesized, and biologically characterized as ...

PubMed

55
Pin1 promotes production of Alzheimer's amyloid {beta} from {beta}-cleaved amyloid precursor protein
2005-10-21

Here we show that prolyl isomerase Pin1 is involved in the A{beta} production central to the pathogenesis of Alzheimer's disease. Enzyme immunoassay of brains of the Pin1-deficient mice revealed that production of A{beta}40 and A{beta}42 was lower than that of the wild-type mice, indicating that Pin1 ...

Energy Citations Database

56
Intrinsic thermal expansivity and hydrational properties of amyloid peptide Abeta42 in liquid water.
2008-11-21

Volumetric and conformational properties of the amyloid beta(1-42) peptide (Abeta(42)) are studied in relation to the properties of hydration water in a wide temperature range by computer simulations. The apparent volume of Abeta(42), which is the change in the total volume of the solution due to the presence of Abeta(42), ...

PubMed

57
High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB.
2007-06-22

The beta-amyloid peptide (Abeta) is considered responsible for the pathogenesis of Alzheimer's disease. Despite the magnitude of reports describing a neurotoxic role of extracellular Abeta, the role for intracellular Abeta (iAbeta) has not been elucidated. We previously demonstrated that in rat pheochromocytoma ...

PubMed

58
Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line.
2009-09-29

Pathological studies have determined that fibrillar forms of amyloid-beta protein (Abeta) comprise the characteristic neuritic plaques in Alzheimer's disease (AD). These studies have also revealed significant inflammatory markers such as activated microglia and cytokines surrounding the plaques. Although the plaques are a hallmark of AD, they are only part of an array of ...

PubMed

59
Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries.
2009-08-01

Increasing evidence suggests that the aggregation of the small peptide Abeta42 plays an important role in the development of Alzheimer's disease. Inhibiting the initial aggregation of Abeta42 may be an effective treatment for preventing, or slowing, the onset of the disease. Using an in vivo screen based on the enzyme EGFP, we have searched through two ...

PubMed

60
Polymorphism of amyloid-beta fibrils and its effects on human erythrocyte catalase binding.
2009-07-16

The Alzheimer's amyloid-beta (Abeta) peptide exists as a number of naturally occurring forms due to differential proteolytic processing of its precursor molecule. Many of the Abeta peptides of different lengths form fibrils in vitro, which often show polymorphisms in the fibril structure. This study presents a TEM based analysis of ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
61
Protein L-isoaspartyl O-methyltransferase inhibits amyloid beta fibrillogenesis in vitro.
2011-07-01

Fibrillar aggregates of beta-amyloid peptide (Abeta) are major constituents of the senile plaques found in the brains of patients suffering from Alzheimer's disease (AD). Previous studies have shown that spontaneous isomerization or racemization of aspartyl residues in Abeta peptides leads to conformational changes in the secondary structure and increased ...

PubMed

62
Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk.
2009-11-05

An emerging body of evidence is consistent with the hypothesis that dietary fats influence Alzheimer's disease (AD) risk, but less clear is the mechanisms by which this occurs. Alzheimer's is an inflammatory disorder, many consider in response to fibrillar formation and extracellular deposition of amyloid-beta (Abeta). Alternatively, amyloidosis could notionally be a secondary ...

PubMed

63
Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.
2008-09-24

The use of quantitative endophenotypes in genetic studies may provide greater power, allowing for the use of powerful statistical methods and a biological model for the effects of the disease-associated genetic variation. Cerebrospinal fluid (CSF) amyloid beta (Abeta) levels are promising endophenotypes for late-onset Alzheimer's disease (LOAD) and show ...

PubMed

64
In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents.
2010-01-01

Alzheimer's disease (AD) is a devastating age-related neurodegenerative disease. Age is the main risk factor for sporadic AD, which is the most prevalent type. Amyloid-beta peptide (Abeta) neurotoxicity is the proposed first step in a cascade of deleterious events leading to AD pathology and dementia. Glial cells play an important role in these changes. Astrocytes provide ...

PubMed

65
Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways.
2009-06-23

Disruption of the postsynaptic density (PSD), a network of scaffold proteins located in dendritic spines, is thought to be responsible for synaptic dysfunction and loss in early-stage Alzheimer's disease (AD). Extending our previous demonstration that derangement of the PSD by soluble amyloid-beta (Abeta) involves proteasomal degradation of PSD-95, a protein important for ...

PubMed

66
Wnt signaling in neuroprotection and stem cell differentiation.
2008-08-19

In the past several years, we postulated that the loss of Wnt signaling was implicated in the pathology of Alzheimer's disease (AD). Since then, our lab and other groups have confirmed the involvement of the Wnt signaling in some aspects of AD. So far, we have demonstrated that activation of Wnt signaling protects neurons against neurotoxic injuries, including both amyloid-beta ...

PubMed

67
Structural determination of Abeta25-35 micelles by molecular dynamics simulations.
2010-07-21

Amyloid-beta (Abeta) peptides and other amyloidogenic proteins can form a wide range of soluble oligomers of varied morphologies at the early aggregation stage, and some of these oligomers are biologically relevant to the pathogenesis of Alzheimer's disease. Spherical micelle-like oligomers have been often observed ...

PubMed

68
Polymorphic triple beta-sheet structures contribute to amide H/D exchange protection in Alzheimer's amyloid beta42.
2011-08-01

Characterization of the polymorphic structural range of A-beta oligomers is important to the understanding of the mechanisms of toxicity. Yet, for highly polymorphic ensembles, experimental structural elucidation is difficult. Here we use a combination of NMR solvent protection experiments and computational structural screening to identify major species in ...

PubMed

69
Isoflurane and desflurane at clinically relevant concentrations induce amyloid {beta}-peptide oligomerization: An NMR study
2009-02-13

Current understanding on Alzheimer's disease (AD) reveals that soluble amyloid {beta}-peptide (A{beta}) oligomeric formation plays an important role in AD pathophysiology. A potential role for several inhaled anesthetics in promoting A{beta} oligomer formation has been suggested. Using a nuclear magnetic resonance (NMR) study, ...

Energy Citations Database

70
Energy landscapes of the monomer and dimer of the Alzheimer's peptide Abeta(1-28).
2008-03-28

The cytotoxicity of Alzheimer's disease has been linked to the self-assembly of the 4042 amino acid of the amyloid-beta (Abeta) peptide into oligomers. To understand the assembly process, it is important to characterize the very first steps of aggregation at an atomic level of detail. Here, we focus on the N-terminal fragment 1-28, known to form fibrils in ...

PubMed

71
Alzheimer's disease: synapses gone cold.
2011-08-26

ABSTRACT: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by insidious cognitive decline and memory dysfunction. Synapse loss is the best pathological correlate of cognitive decline in AD and mounting evidence suggests that AD is primarily a disease of synaptic dysfunction. Soluble oligomeric forms of amyloid beta (Abeta), the peptide that ...

PubMed

72
New stilbene dimers against amyloid fibril formation.
2009-09-24

Twenty stilbene derivatives and moracin M extracted from natural products were tested against amyloid-beta peptide (Abeta) aggregation. Results of stilbene monomer derivatives indicated that interaction with resveratrol and piceid was specific. Concerning oligomers, scirpusin A and epsilon-viniferin glucoside demonstrated a strong inhibition of the ...

PubMed

73
Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-beta.
2009-05-12

The cellular generation of toxic metabolites and subsequent detoxification failure can cause the uncontrolled accumulation of these metabolites in cells, leading to cellular dysfunction. Amyloid-beta protein (Abeta), a normal metabolite of neurons, tends to form toxic oligomeric structures that cause neurodegeneration. It is unclear how healthy neurons control the levels of ...

PubMed

74
Characterizations of distinct amyloidogenic conformations of the Abeta (1-40) and (1-42) peptides.
2006-12-15

Major constituents of the amyloid plaques found in the brain of Alzheimer's patients are the 39-43 residue beta-amyloid (Abeta) peptides. Extensive in vitro as well as in vivo biochemical studies have shown that the 40- and 42-residue Abeta peptides play major roles in the neurodegenerative pathology of Alzheimer's disease. Although the two ...

PubMed

75
Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?
2008-06-01

Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-beta (Abeta(42)) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimer's disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the ...

PubMed

76
Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity.
2006-01-01

Teas represent a large family of plants containing high amounts of polyphenols that may confer health benefits in various diseases. Recently, it has been hypothesized that tea consumption may also reduce the risk of age-related neurodegenerative pathologies. Considering the deleterious role of beta-amyloid (Abeta) in the aetiology of Alzheimer's disease (AD), we investigated ...

PubMed

77
Structures of A[beta]-Related Peptide−Monoclonal Antibody Complexes
2009-06-15

Passive immunotherapy (PI) is being explored as a potential therapeutic against Alzheimer's disease. The most promising antibodies (Abs) used in PI target the EFRH motif of the A{beta} N-terminus. The monoclonal anti-A{beta} Ab PFA1 recognizes the EFRH epitope of A{beta}. PFA1 has a high affinity for A{beta} fibrils and ...

Energy Citations Database

78
How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40).
2010-02-05

Membrane lipids play a pivotal role in the pathogenesis of Alzheimer's disease, which is associated with conformational changes, oligomerization and/or aggregation of Alzheimer's beta-amyloid (Abeta) peptides. Yet conflicting data have been reported on the respective effect of cholesterol and glycosphingolipids (GSLs) on the supramolecular assembly of ...

PubMed

79
Supplemental Materials A. Details of the finite field calculations

for planar and linear oligomers with n=2, 4, and 8. The calculations include all and * orbitals that obtained from the energy derivative method shows substantial oscillations. For each oligomer of the PPV-8 and OPPV-9 oligomers as a function of the strength of the dielectric screening. Figure 6

E-print Network

80
The mitochondrial secret(ase) of Alzheimer's disease.
2010-01-01

Alzheimer's disease (AD) is a neurodegenerative disorder characterized clinically by progressive decline in memory and cognition and pathologically by extracellular amyloid-beta (Abeta) deposits and intraneuronal aggregates of hyperphosphorylated tau. Since its proposal in 1992, the amyloid cascade hypothesis implicates Abeta overproduction as a causative ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
81
Reelin signaling antagonizes beta-amyloid at the synapse.
2009-09-02

Abnormal processing of the amyloid precursor protein (APP) and beta-amyloid (Abeta) plaque accumulation are defining features of Alzheimer disease (AD), a genetically complex neurodegenerative disease that is characterized by progressive synapse loss and neuronal cell death. Abeta induces synaptic dysfunction in part by altering the endocytosis and ...

PubMed

82
Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease Inhibitor
2008-08-06

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of amyloid ?-peptide (A-Beta) in the brain. Transthyretin (TTR) is a tetrameric protein of about 55 kDa mainly produced in the liver and choroid plexus of the brain. The known physiological functions of TTR are the transport of thyroid hormone T4 and retinol, through ...

PubMed Central

83
Detection of Alzheimer's amyloid beta aggregation by capturing molecular trails of individual assemblies
2008-12-12

Assembly of Amyloid beta (A{beta}) peptides, in particular A{beta}-42 is central to the formation of the amyloid plaques associated with neuro-pathologies such as Alzheimer's disease (AD). Molecular assembly of individual A{beta}-42 species was observed using a simple fluorescence microscope. From the molecular movements (aka ...

Energy Citations Database

84
Chronic corticosterone administration dose-dependently modulates Abeta(1-42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis.
2000-06-01

The impact of glucocorticoids on beta-amyloid(1-42) (Abeta(1-42)) and NMDA-induced neurodegeneration was investigated in vivo. Abeta(1-42) or NMDA was injected into the cholinergic magnocellular nucleus basalis in adrenalectomized (ADX) rats, ADX rats supplemented with 25%, 100%, 2x100% corticosterone pellets, or sham-ADX controls. ...

PubMed

85
Copper Reduces A{beta} Oligomeric Species and Ameliorates Neuromuscular Synaptic Defects in a C. elegans Model of Inclusion Body Myositis.
2011-07-13

Alzheimer's disease and inclusion body myositis (IBM) are disorders frequently found in the elderly and characterized by the presence of amyloid-? peptide (A?) aggregates. We used Caenorhabditis elegans that express A? in muscle cells as a model of IBM, with the aim of analyzing A?-induced muscle pathology and evaluating the consequences of modulating A? aggregation. First, we tested whether the ...

PubMed

86
Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave-ripple complexes.
2009-05-27

One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques in brains of affected patients. Several recent studies provided evidence that soluble oligomer forms of amyloid-beta (Abeta) rather than plaques determine cognitive decline. In vitro studies using artificial Abeta oligomer ...

PubMed

87
Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease.
2009-07-21

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration of cognitive abilities, accumulation of the amyloid-beta-peptide (Abeta) and synaptic alterations. Treatment with lithium has been shown to provide neuroprotection against several insults, including protection against Abeta neurotoxicity in vitro. ...

PubMed

88
Development and validation of a yeast high-throughput screen for inhibitors of A{beta}42 oligomerization.
2011-08-01

Recent reports point to small soluble oligomers, rather than insoluble fibrils, of amyloid ? (A?), as the primary toxic species in Alzheimer's disease. Previously, we developed a low-throughput assay in yeast that is capable of detecting small A?(42) oligomer formation. Specifically, A?(42) fused to the functional release factor domain of yeast ...

PubMed

89
Structural optimization and biological evaluation of substituted bisphenol A derivatives as beta-amyloid peptide aggregation inhibitors.
2010-08-12

The aggregation of Abeta is a crucial step in the etiology of Alzheimer's disease. Our previous work showed that Abeta undergoes alpha-helix/beta-sheet intermediate structures during the conformational transition, and an Abeta aggregation inhibitor (1) was discovered by targeting the intermediates. Here, structure ...

PubMed

90
Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity.
2010-02-01

Amyloid-beta (Abeta) peptides play a central role in the pathogenesis of Alzheimer's disease. There is accumulating evidence that supports the notion that the toxicity associated with human Abeta (both 40 and 42) is dependent on its superoxide dismutase (SOD)-like activity. We developed a novel screening method involving phage display technology to ...

PubMed

91
Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease.
2009-03-23

The mechanism by which aggregates of the beta-amyloid peptide (Abeta) mediate their toxicity is uncertain. We show here that the expression of the 42-amino-acid isoform of Abeta (Abeta(1-42)) changes the expression of genes involved in oxidative stress in a Drosophila model of Alzheimer's disease. A subsequent ...

PubMed

92
Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ current.
2005-11-04

Control of neuronal spiking patterns resides, in part, in the type and degree of expression of voltage-gated K(+) channel subunits. Previous studies have revealed that soluble forms of the Alzheimer's disease associated amyloid beta protein (Abeta) can increase the 'A'-type current in neurones. In this study, we define the molecular basis for this increase and ...

PubMed

93
AlphaB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid beta-peptide and beta2-microglobulin.
2005-12-15

AlphaB-crystallin, a small heat-shock protein, exhibits molecular chaperone activity. We have studied the effect of alphaB-crystallin on the fibril growth of the Abeta (amyloid beta)-peptides Abeta-(1-40) and Abeta-(1-42). alphaB-crystallin, but not BSA or hen egg-white lysozyme, prevented the fibril growth of ...

PubMed

94
Role of fibrillar Abeta25-35 in the inflammation induced rat model with respect to oxidative vulnerability.
2005-06-01

The major pathological ramification of Alzheimer's disease (AD) is accumulation of beta-Amyloid (Abeta) peptides in the brain. An emerging therapeutic approach for AD is elimination of excessive Ass peptides and preventing its re-accumulation. Immunization is the most effective strategy in removing preexisting cerebral Abetas and improving the cognitive ...

PubMed

95
[Development of new drugs for Alzheimer's disease].
2010-07-01

Currently, only donepezil is available for the treatment of Alzheimer disease (AD) in Japan. Clinical trials of galantamine, rivastigmine, and memantine have been completed in Japan, and patients are awaiting government approval for the use of these drugs. The herbal medicine yokukansan was found to be effective for behavioral and psychological symptoms of dementia (BPSD) in patients, and ...

PubMed

96
Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity.
2010-01-19

The formation of extracellular amyloid plaques is a common patho-biochemical event underlying several debilitating human conditions, including Alzheimer's disease (AD). Considerable evidence implies that AD damage arises primarily from small oligomeric amyloid forms of Abeta peptide, but the precise mechanism of pathogenicity remains to be established. Using a cell culture ...

PubMed

97
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.
1998-10-23

The amyloid protein, Abeta, which accumulates in the brains of Alzheimer patients, is derived by proteolysis of the amyloid protein precursor (APP). APP can undergo endoproteolytic processing at three sites, one at the amino terminus of the Abeta domain (beta-cleavage), one within the Abeta domain (alpha-cleavage), and one at the ...

PubMed

98
Effect of purple sweet potato anthocyanins on beta-amyloid-mediated PC-12 cells death by inhibition of oxidative stress.
2009-09-22

Amyloid-beta peptide (Abeta) is known to induce the redox imbalance, mitochondrial dysfunction and caspase activation, resulting in neuronal cell death. Treatment with antioxidants provided a new therapeutic strategy for Alzheimer's disease (AD) patients. Here we investigate the effects of purple sweet potato anthocyanins (PSPA), the known strong free radical scavengers, on ...

PubMed

99
Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis.
1998-10-27

Amyloid beta peptide (Abeta) is thought to play a central role in the pathogenesis of Alzheimer disease (AD). How Abeta induces neurodegeneration in AD is not known. A connection between AD and cholesterol metabolism is suggested by the finding that people with the apolipoprotein E4 allele, a locus coding for a cholesterol-transporting lipoprotein, have a ...

PubMed

100
The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism.
2007-11-13

Neuritic abnormalities are a major hallmark of Alzheimer's disease (AD) pathology. Accumulation of beta-amyloid protein (Abeta) in the brain causes changes in neuritic processes in individuals with this disease. In this study, we show that Abeta decreases neurite outgrowth from SH-SY5Y human neuroblastoma cells. To explore molecular ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
101
Protective effects of Angelica sinensis extract on amyloid beta-peptide-induced neurotoxicity.
2008-04-29

The protective effects of alcohol extract from the root of Angelica sinensis (AS) on beta-amyloid peptide (Abeta)-induced toxicity and the mechanism of these effects were investigated. Abeta is a pathological hallmark of Alzheimer's disease; it decreased viability of Neuro 2A cells in a concentration-dependent manner with IC(50) of 14.9 microM. AS extract ...

PubMed

102
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
2005-11-16

During the development of in vivo amyloid imaging agents, an effort was made to use micro-positron emission tomography (PET) imaging in the presenilin-1 (PS1)/amyloid precursor protein (APP) transgenic mouse model of CNS amyloid deposition to screen new compounds and further study Pittsburgh Compound-B (PIB), a PET tracer that has been shown to be retained well in amyloid-containing areas of ...

PubMed

103
Amyloid-[beta]�Anti-Amyloid-[beta] Complex Structure Reveals an Extended Conformation in the Immunodominant B-Cell Epitope
2008-04-29

Alzheimer's disease (AD) is the most common form of dementia. Amyloid-{beta} (A{beta}) peptide, generated by proteolytic cleavage of the amyloid precursor protein, is central to AD pathogenesis. Most pharmaceutical activity in AD research has focused on A{beta}, its generation and clearance from the brain. In particular, there is much interest in ...

Energy Citations Database

104
The second Cu(II)-binding site in a proton-rich environment interferes with the aggregation of amyloid-beta(1-40) into amyloid fibrils.
2009-11-17

The overall morphology and Cu(II) ion coordination for the aggregated amyloid-beta(1-40) [Abeta(1-40)] in N-ethylmorpholine (NEM) buffer are affected by Cu(II) ion concentration. This effect is investigated by transmission electron microscopy (TEM), atomic force microscopy (AFM), and electron spin echo envelope modulation (ESEEM) spectroscopy. At lower than equimolar ...

PubMed

105
Urea modulation of beta-amyloid fibril growth: experimental studies and kinetic models.
2004-09-30

Aggregation of beta-amyloid (Abeta) into fibrillar deposits is widely believed to initiate a cascade of adverse biological responses associated with Alzheimer's disease. Although it was once assumed that the mature fibril was the toxic form of Abeta, recent evidence supports the hypothesis that Abeta oligomers, ...

PubMed

106
The Redox Chemistry of Metallophthalocyanines in Solution
1992-05-19

... stabilized [75]. Table 3 Silicon Phthalocyanine Oligomers Showing Mixed-Valence Behavior (In Dichloromethane). Species ...

DTIC Science & Technology

107
The Prebiotic Chemistry of Sugars

Detailed studies of the kinetics of this reaction now show that the reactive species is not formaldehyde itself, but rather a short fragment of the oligomer ...

NASA Website

108
Synthesis of Novel Electrically Conducting Polymers: Potential ...

furans, and certain oligomers of these compounds showed electrical conductivity ... and furans were synthesized by a Wittig reaction as outlined in Scheme ...

NASA Website

109
Soluble state high resolution atomic force microscopy study of Alzheimer�s ?-amyloid oligomers
2009-11-02

We report here the direct observation of high resolution structures of assemblies of Alzheimer ?-amyloid oligomers and monomers using liquid atomic force microscopy (AFM). Visualization of nanoscale features of A? oligomers (also known as ADDLs) was carried out in tapping mode AFM in F12 solution. Our results indicate that ADDL preparations exist in ...

PubMed Central

110
Soluble state high resolution atomic force microscopy study of Alzheimer's ?-amyloid oligomers
2009-11-01

We report here the direct observation of high resolution structures of assemblies of Alzheimer ?-amyloid oligomers and monomers using liquid atomic force microscopy (AFM). Visualization of nanoscale features of A? oligomers (also known as ADDLs) was carried out in tapping mode AFM in F12 solution. Our results indicate that ADDL preparations exist in ...

NASA Astrophysics Data System (ADS)

111
Polymerization on the Rocks: Theoretical Introduction
1998-06-01

It is difficult if not impossible to synthesize long polymers of amino acids, nucleotides, etc., in homogeneous aqueous solution. We suggest that long polymers were synthesized on the surface of minerals in a prebiotic process analogous to solid-phase synthesis. Provided that the affinity of a mineral for an oligomer increases with the length of the ...

NASA Astrophysics Data System (ADS)

112
Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.
2009-11-04

We have previously shown that a subpopulation of naturally occurring human IgGs were cross-reactive against conformational epitopes on pathologic aggregates of Abeta, a peptide that forms amyloid fibrils in the brains of patients with Alzheimer disease, inhibited amyloid fibril growth, and dissociated amyloid in vivo. Here, we describe similar anti-amyloidogenic activity that ...

PubMed

113
The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42.
2008-06-25

Recent studies have demonstrated that amyloid-beta1-42 (Abeta1-42) binds to the nicotinergic alpha7 acetylcholine receptor (alpha7 nAChR) and that the application of Abeta1-42 to cells inhibits the function of the alpha7 nAChR. The in vivo consequences of the pharmacological activation of the alpha7 nAChR have not been examined. The aim of this study has ...

PubMed

114
Downregulation of CREB expression in Alzheimer's brain and in Abeta-treated rat hippocampal neurons.
2011-08-19

ABSTRACT: BACKGROUND: Oxidative stress plays an important role in neuronal dysfunction and neuron loss in Alzheimer's brain. Previous studies have reported downregulation of CREB-mediated transcription by oxidative stress and Abeta. The promoter for CREB itself contains cyclic AMP response elements. Therefore, we examined the expression of CREB in the hippocampal neurons of ...

PubMed

115
Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy.
2005-01-19

Idiopathic or primary angiitis of the CNS (PACNS) and cerebral amyloid angiopathy (CAA) are unusual vasculopathies generally regarded as unrelated disorders. A few case reports have, however, described granulomatous angiitis in patients with sporadic, amyloid beta peptide (Abeta)-related CAA. Here we describe the clinical, neuroradiological and neuropathological features of ...

PubMed

116
A[Beta] Deposits in Older Non-Demented Individuals with Cognitive Decline Are Indicative of Preclinical Alzheimer's Disease
2008-05-01

Approximately 30% of healthy persons aged over 75 years show A[beta] deposition at autopsy. It is postulated that this represents preclinical Alzheimer's disease (AD). We evaluated the relationship between A[beta] burden as assessed by PiB PET and cognitive decline in a well-characterized, non-demented, elderly cohort. PiB PET studies ...

ERIC Educational Resources Information Center

117
Detergent-like interaction of Congo red with the amyloid beta peptide.
2010-02-23

Accumulating evidence links prefibrillar oligomeric species of the amyloid beta peptide (Abeta) to cellular toxicity in Alzheimer's disease, potentially via disruption of biological membranes. Congo red (CR) affects protein aggregation. It is known to self-associate into micelle-like assemblies but still reduces the toxicity of Abeta aggregates in cell ...

PubMed

118
Low-resolution structure of a vesicle disrupting ?-synuclein oligomer that accumulates during fibrillation
2011-02-22

One of the major hallmarks of Parkinson disease is aggregation of the protein ?-synuclein (?SN). Aggregate cytotoxicity has been linked to an oligomeric species formed at early stages in the aggregation process. Here we follow the fibrillation process of ?SN in solution over time using small angle X-ray scattering and resolve four major coexisting species in the fibrillation process, namely ...

PubMed Central

119
Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation.
2011-02-07

One of the major hallmarks of Parkinson disease is aggregation of the protein ?-synuclein (?SN). Aggregate cytotoxicity has been linked to an oligomeric species formed at early stages in the aggregation process. Here we follow the fibrillation process of ?SN in solution over time using small angle X-ray scattering and resolve four major coexisting species in the fibrillation process, namely ...

PubMed

120
Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells.
2005-08-01

The present study was performed to examine how the stimulation of gamma-aminobutyric acid (GABA) receptor affects amyloid beta protein (25-35) (Abeta (25-35)), a synthetic 25-35 amyloid peptide, -induced neurotoxicity using cultured rat cortical neurons. Abeta (25-35) produced a concentration-dependent reduction of cell viability, which was significantly ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
121
gamma-Secretase as a therapeutic target in Alzheimer's disease.
2010-04-01

gamma-Secretase is an intramembranous multi-protein complex that cleaves many type-I proteins with critical roles in neuronal function. In Alzheimer's disease (AD) interest in gamma-secretase comes, in part, from the fact that this complex is responsible for the last cleavage step of the amyloid precursor protein (APP) that generates the amyloid-beta peptide (Abeta). ...

PubMed

122
Reduction of calcium release from the endoplasmic reticulum could only provide partial neuroprotection against beta-amyloid peptide toxicity.
2003-12-01

Beta-amyloid (Abeta) peptide has been suggested to play important roles in the pathogenesis of Alzheimer's disease (AD). Abeta peptide neurotoxicity was shown to induce disturbance of cellular calcium homeostasis. However, whether modulation of calcium release from the endoplasmic reticulum (ER) can protect neurons from Abeta toxicity ...

PubMed

123
Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
2006-02-01

Neocortical beta-amyloid (Abeta) aggregates in Alzheimer's disease (AD) are enriched in transition metals that mediate assembly. Clioquinol (CQ) targets metal interaction with Abeta and inhibits amyloid pathology in transgenic mice. Here, we investigated the binding properties of radioiodinated CQ ([(125)I]CQ) to different in vitro and in vivo Alzheimer ...

PubMed

124
Inhibitory effect of green tea extract on beta-amyloid-induced PC12 cell death by inhibition of the activation of NF-kappaB and ERK/p38 MAP kinase pathway through antioxidant mechanisms.
2005-09-08

Beta-amyloid peptide (Abeta) is considered responsible for the pathogenesis of Alzheimer's disease (AD). Several lines of evidence support that Abeta-induced cytotoxicity is mediated through the generation of reactive oxygen species (ROS). Thus, agents that scavenge ROS level may usefully impede the development or progress of AD. Green tea extract has been ...

PubMed

125
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
2003-02-03

Transgenic PDAPP mice, which express a disease-linked isoform of the human amyloid precursor protein, exhibit CNS pathology that is similar to Alzheimer's disease. In an age-dependent fashion, the mice develop plaques containing beta-amyloid peptide (Abeta) and exhibit neuronal dystrophy and synaptic loss. It has been shown in previous studies that pathology can be prevented ...

PubMed

126
Calcium alginate entrapped preparations of Aspergillus oryzae beta galactosidase: its stability and applications in the hydrolysis of lactose.
2007-01-16

Insoluble concanavalin A-beta galactosidase complex was obtained by using jack bean extract and this complex was crosslinked with glutaraldehyde, in order to maintain the integrity of complex in the presence of its substrate or products. Concanavalin A-beta galactosidase complex retained 92% of the initial enzyme activity whereas crosslinked complex ...

PubMed

127
Caffeine and coffee as therapeutics against Alzheimer's disease.
2010-01-01

Epidemiologic studies have increasingly suggested that caffeine/coffee could be an effective therapeutic against Alzheimer's disease (AD). We have utilized a transgenic mouse model for AD in well-controlled studies to determine if caffeine and/or coffee have beneficial actions to protect against or reverse AD-like cognitive impairment and AD pathology. AD mice given caffeine in their drinking ...

PubMed

128
Studies on the structure of HCN oligomers
1987-09-01

The structure of the water-insoluble fraction of HCN oligomers (azulmic acid) was studied by IR, NMR, gel permeation chromatography, and chemical methods. The results show that nearly half of the nitrogen atoms contained in the oligomers are of the primary amino type and the other half are involved in -C = N- type bonding. It was found ...

NASA Astrophysics Data System (ADS)

129
Monte Carlo study of oligopyrroles in condensed phases.
2010-07-21

A classical model potential to simulate pyrrole oligomers in condensed phases is developed in this work. The new potential contains ten parameters that are optimized on a database of energy points calculated within the density functional theory approach. Based on this potential the condensed phase of systems composed of pyrrole oligomers with 4 and 12 ...

PubMed

130
Monte Carlo study of oligopyrroles in condensed phases
2010-07-01

A classical model potential to simulate pyrrole oligomers in condensed phases is developed in this work. The new potential contains ten parameters that are optimized on a database of energy points calculated within the density functional theory approach. Based on this potential the condensed phase of systems composed of pyrrole oligomers with 4 and 12 ...

NASA Astrophysics Data System (ADS)

131
Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides.
2009-01-12

The assembly of amyloidogenic proteins into toxic oligomers is a seminal event in the pathogenesis of protein misfolding diseases, including Alzheimer's, Parkinson's, and Huntington's diseases, hereditary amyotrophic lateral sclerosis, and type 2 diabetes. Owing to the metastable nature of these protein assemblies, it is difficult to assess their oligomer ...

PubMed

132
Amyloid-beta42 oligomer structures from fibrils: a systematic molecular dynamics study.
2010-02-18

Recent experimental data demonstrate that small, soluble amyloid-beta42 oligomers play an important role in Alzheimer's disease because they exhibit neurotoxic properties and also act as seed for fibril growth. We performed all-atom molecular dynamics simulations in explicit solvent of 0.7 micros in total on five Abeta9-42 oligomers ...

PubMed

133
Purification of Acetylene-Terminated Polyimide Oligomers.
1979-01-01

Acetylene-terminated polyimide oligomers show promise as matrix resins for advanced aircraft and aerospace systems. The materials have the potential of curing without the evolution of volatile by-products, thereby obviating the problem of void formation i...

National Technical Information Service (NTIS)

134
Structural requirements for antimicrobial versus chemoattractant activities for dermaseptin S9.
2008-07-10

Dermaseptin S9 (Drs S9), GLRSKIWLWVLLMIWQESNKFKKM, isolated from frog skin, does not resemble any of the cationic and amphipathic antimicrobial peptides identified to date, having a highly hydrophobic core sequence flanked at either side by cationic termini. Previous studies [Lequin O, Ladram A, Chabbert A, Bruston F, Convert O, Vanhoye D, Chassaing G, Nicolas P & Amiche M (2006) ...

PubMed

135
In vivo demonstration that ?-synuclein oligomers are toxic
2011-03-08

The aggregation of proteins into oligomers and amyloid fibrils is characteristic of several neurodegenerative diseases, including Parkinson disease (PD). In PD, the process of aggregation of ?-synuclein (?-syn) from monomers, via oligomeric intermediates, into amyloid fibrils is considered the disease-causative toxic mechanism. We developed ?-syn mutants that promote ...

PubMed Central

136
Amplified spontaneous emission from a new 4-triarylamine substituted 1,8-naphthalimide semiconductor oligomer
2005-06-01

Amplified spontaneous emission has been observed in a new semiconductor oligomer of 2-decyl-6-{[4'-(naphthalene-1-yl-phenyl-amino)-biphenyl-4-yl]-[4-(naphthalene-1-yl-phenyl-amino)-phenyl]-amino}-benzo[de]isoquinoline-1,3-dione (4-triarylamine substituted 1,8-naphthalimide TAANPI) doped polymer films pumped by the second harmonic of a Nd:YAG laser. The dependence of the ...

NASA Astrophysics Data System (ADS)

137
Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity.
2008-09-24

Epidemiological evidence suggests that moderate consumption of red wine reduces the incidence of Alzheimer disease (AD). To study the protective effects of red wine, experiments recently were executed in the Tg2576 mouse model of AD. These studies showed that a commercially available grape seed polyphenolic extract, MegaNatural-AZ (MN), significantly attenuated AD-type ...

PubMed

138
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
2003-01-01

M1 muscarinic receptors (M1 mAChRs) play a role in an apparent linkage of three major hallmarks of Alzheimer's disease (AD): beta-amyloid (Abeta) peptide; tau hyperphosphorylation and paired helical filaments (PHFs); and loss of cholinergic function conducive to cognitive impairments. We evaluated the M1 muscarinic agonists AF102B (Cevimeline, EVOXAC trade mark : prescribed ...

PubMed

139
Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.
2008-06-01

Several neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's and prion diseases, are characterized pathognomonically by the presence of intra- and/or extracellular lesions containing proteinaceous aggregates, and by extensive neuronal loss in selective brain regions. Related non-neuropathic systemic diseases, e.g., light-chain and senile systemic amyloidoses, and other ...

PubMed

140
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
2009-12-10

Alzheimer's disease (AD) is a member of a category of neurodegenerative diseases characterized by the conformational change of a normal protein into a pathological conformer with a high beta-sheet content that renders it resistant to degradation and neurotoxic. In the case of AD the normal soluble amyloid beta (sAbeta) peptide is converted into oligomeric/fibrillar ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
141
A Study of the Process and Causes of Abeta(25-35) Amyloid Formation
2009-12-01

Amyloid fibrils results from a type of ordered polypeptide aggregation that is associated with ailments such as Alzheimer's disease (AD). Annually, millions of people in the United States alone develop and die from AD. Therefore, it is necessary to understand not only the process of amyloid formation, but also the causes of this specific type of aggregation. This study used ...

E-print Network

142
Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice.
2010-01-01

Intrahippocampal injections of aggregated amyloid-beta (Abeta)1-42 in rats result in memory impairment and in reduction of hippocampal 5-HT2A receptor levels. In order to investigate how changes in 5-HT2A levels and functionality relate to the progressive accumulation of Abeta protein, we studied 5-HT2A receptor regulation in double transgenic ...

PubMed

143
Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.
2009-05-21

Valid animal models for a specific human disease are indispensable for development of new therapeutic agents. The conclusions drawn from animal models largely depend on the validity of the model. Several studies have shown that administration of Abeta into the brain causes some of the pathological events observed in Alzheimer disease (AD). However, the validity of these models ...

PubMed

144
Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide.
2005-02-16

Although metal ions such as Cu(2+), Zn(2+), and Fe(3+) are implicated to play a key role in Alzheimer disease, their role is rather complex, and comprehensive understanding is not yet obtained. We show that Cu(2+) and Zn(2+) but not Fe(3+) renders the amyloid beta peptide, Abeta(1-40), nonfibrillogenic in nature. However, preformed fibrils of ...

PubMed

145
Laminar specific loss of isocortical presenilin 1 immunoreactivity in Alzheimer's disease. Correlations with the amyloid load and the density of tau-positive neurofibrillary tangles.
2000-04-01

Presenilin 1 has been shown to be mutated in a high proportion of cases of familial Alzheimer's disease. Immunoreactive epitopes of the protein have been found mainly in neurones devoid of neurofibrillary tangles - an observation that has led to the conclusion that presenilin 1 could have a protective role. In this study, the relationship between deposits of Abeta peptide ...

PubMed

146
Engineering Metal Ion Coordination to Regulate Amyloid Fibril Assembly And Toxicity
2009-06-02

Protein and peptide assembly into amyloid has been implicated in functions that range from beneficial epigenetic controls to pathological etiologies. However, the exact structures of the assemblies that regulate biological activity remain poorly defined. We have previously used Zn{sup 2+} to modulate the assembly kinetics and morphology of congeners of the amyloid {beta} peptide ...

Energy Citations Database

147
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.
1997-05-13

In Alzheimer disease (AD), neurons are thought to be subjected to the deleterious cytotoxic effects of activated microglia. We demonstrate that binding of amyloid-beta peptide (Abeta) to neuronal Receptor for Advanced Glycation Endproduct (RAGE), a cell surface receptor for Abeta, induces macrophage-colony stimulating factor (M-CSF) by an oxidant ...

PubMed

148
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.
2008-07-29

Reduction of Abeta deposition is a major therapeutic strategy in Alzheimer's disease (AD). The concentration of Abeta in the brain is modulated not only by Abeta production but also by its degradation. One of the proteases involved in the degradation of Abeta peptides is endothelin-converting enzyme (ECE). In this ...

PubMed

149
Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death.

Amyloid beta-peptide [Abeta(1-42)] is central to the pathogenesis of Alzheimer's disease (AD), and the AD brain is under intense oxidative stress, including membrane lipid peroxidation. Abeta(1-42) causes oxidative stress in and neurotoxicity to neurons in mechanisms that are inhibited by Vitamin E and involve the single methionine residue of this peptide. ...

PubMed

150
Loss of Aip1 reveals a role in maintaining the actin monomer pool and an in vivo oligomer assembly pathway
2010-03-22

Although actin filaments can form by oligomer annealing in vitro, they are assumed to assemble exclusively from actin monomers in vivo. In this study, we show that a pool of actin resistant to the monomer-sequestering drug latrunculin A (lat A) contributes to filament assembly in vivo. Furthermore, we show that the cofilin accessory ...

PubMed Central

151
Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption.
2009-12-23

Synaptic degeneration, including impairment of synaptic plasticity and loss of synapses, is an important feature of Alzheimer disease pathogenesis. Increasing evidence suggests that these degenerative synaptic changes are associated with an accumulation of soluble oligomeric assemblies of amyloid beta (Abeta) known as ADDLs. In primary hippocampal cultures ADDLs bind to a ...

PubMed

152
Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice.
2003-06-01

Calcineurin is a calcium-regulated serine-threonine protein phosphatase that controls developmental and inducible biological responses in diverse cell types, in part through activation of the transcription factor nuclear factor of activated T cells (NFAT). In skeletal muscle, calcineurin has been implicated in the regulation of myoblast differentiation, hypertrophy of mature myofibers, and fiber ...

PubMed

153
A Humanin Derivative Reduces Amyloid Beta Accumulation and Ameliorates Memory Deficit in Triple Transgenic Mice
2011-01-17

Humanin (HN), a 24-residue peptide, was identified as a novel neuroprotective factor and shows anti-cell death activity against a wide spectrum of Alzheimer's disease (AD)-related cytotoxicities, including exposure to amyloid beta (Abeta), in vitro. We previously demonstrated that the injection of S14G-HN, a highly potent HN derivative, into brain ...

PubMed Central

154
Single molecule tracking analysis reveals that the surface mobility of amyloid oligomers is driven by their conformational structure.
2011-07-18

Several models have been proposed to explain the cytotoxicity of A? oligomers. The structural polymorphism of the oligomers can account for the various toxic effects observed. By combining the use of conformation-specific antibodies and single particle tracking techniques, we have investigated the mobility of individual A?1-42 ...

PubMed

155
Age-related changes to TNF receptors affect neuron survival in the presence of beta-amyloid
2008-08-01

Inflammation including local accumulations of tumor necrosis factor alpha (TNF?) is a part of Alzheimer�s disease (AD) pathology and may exacerbate age-related neurodegeneration. Most studies on TNF? and TNF neuronal receptors are conducted using embryonic neurons. Few studies consider age-related deficits that may occur in neurons. Age-related changes in susceptibility to TNF? through TNF ...

PubMed Central

156
Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.
2009-03-01

The vasculotropic E22Q mutant of the amyloid-beta (Abeta) peptide is associated with hereditary cerebral hemorrhage with amyloidosis Dutch type. The cellular mechanism(s) of toxicity and nature of the AbetaE22Q toxic assemblies are not completely understood. Comparative assessment of structural parameters and cell death mechanisms elicited in primary human ...

PubMed

157
Computational Chemistry for the High Power Microwave ...
1999-10-01

... anionic phenols, however, have lower electronic excitation energies than the neutral oligomers and show more overlap with luminol transition states ...

DTIC Science & Technology

158
Stochastic models of receptor oligomerization by bivalent ligand
2006-02-28

In this paper, we develop stochastic models of receptor binding by a bivalent ligand. A detailed kinetic study allows us to analyse the role of cross-linking in cell activation by receptor oligomerization. We show how oligomer formation could act to buffer intracellular signalling against stochastic fluctuations. In addition, we put forward the hypothesis ...

PubMed Central

159
Mapping Conformational Ensembles of A? Oligomers in Molecular Dynamics Simulations
2010-09-22

Although the oligomers formed by A? peptides appear to be the primary cytotoxic species in Alzheimer's disease, detailed information about their structures appears to be lacking. In this article, we use exhaustive replica exchange molecular dynamics and an implicit solvent united-atom model to study the structural properties of A? monomers, dimers, and tetramers. Our analysis ...

PubMed Central

160
Cell death and a-beta levels
2009-12-26

Professor Dennis Selkoe discusses the largely linear relationship between a-beta and cell death in the brain.

NSDL National Science Digital Library

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
161
Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay.
2011-06-07

Amyloid-? peptide (A?) is the amyloid component of senile plaques in Alzheimer disease (AD) brains. Recently a soluble oliomeric form of A? in A? precursor protein transgenic mouse brains and AD brains was identified as a potential causative molecule for memory impairment, suggesting that soluble A? oligomers cause neurodegeneration in AD. Further characterization of this ...

PubMed

162
Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-beta((25-35)).
2009-02-10

The chemical alpha-asarone is an important active substance of the Acori graminei rhizome (AGR). It has pharmacological effects that include antihyperlipidemic, antiinflammatory, and antioxidant activity. Our aim was to study the effects alpha-asarone on nitric oxide (NO) levels in the hippocampus and temporal cortex of the rat after injection of the fraction 25-35 from amyloid-beta ...

PubMed

163
Differential protection among fractionated blueberry polyphenolic families against DA-, ABeta 42 and LPS-induced decrements in Ca2+ buffering in primary hippocampal cells

It has been postulated that at least part of the loss of cognitive function in aging may be the result of deficits in Ca2+ recovery (CAR) and increased oxidative/inflammatory (OX/INF) stress signaling. However, previous research showed that aged animals supplemented with blueberry (BB) extract, show...

Technology Transfer Automated Retrieval System (TEKTRAN)

164
Amyloid beta-protein: experiment and theory on the 21-30 fragment.
2009-04-30

The structure of the 21-30 fragment of the amyloid beta-protein (Abeta) was investigated by ion mobility mass spectrometry and replica exchange dynamics simulations. Mutations associated with familial Alzheimer's disease (E22G, E22Q, E22K, and D23N) of Abeta(21-30) were also studied, in order to understand any structural changes that might occur with these ...

PubMed

165
Synthesis and G-Quadruplex-Binding Properties of Defined Acridine Oligomers
2010-06-13

The synthesis of oligomers containing two or three acridine units linked through 2-aminoethylglycine using solid-phase methodology is described. Subsequent studies on cell viability showed that these compounds are not cytotoxic. Binding to several DNA structures was studied by competitive dialysis, which showed a clear affinity for DNA ...

PubMed Central

166
Human apolipoprotein C-I expression in mice impairs learning and memory functions.
2007-12-26

The H2 allele of APOC1, giving rise to increased gene expression of apolipoprotein C-I (apoC-I), is in genetic disequilibrium with the APOE4 allele and may provide a major risk factor for Alzheimer's disease (AD). We found that apoC-I protein is present in astrocytes and endothelial cells within hippocampal regions in both human control and AD brains. Interestingly, apoC-I colocalized with ...

PubMed

167
Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
2010-12-21

The goal of this work is the reduction in the Abeta amyloid peptide burden in brain of Alzheimer's disease (AD) transgenic mice without the concomitant elevation in plasma Abeta amyloid peptide. An anti-Abeta amyloid antibody (AAA) was re-engineered as a fusion protein with a blood-brain barrier (BBB) molecular Trojan horse. The AAA ...

PubMed

168
Receptor-Mediated Abeta Amyloid Antibody Targeting to Alzheimer�s Disease Mouse Brain
2010-12-21

The goal of this work is the reduction in the Abeta amyloid peptide burden in brain of Alzheimer�s disease (AD) transgenic mice without the concomitant elevation in plasma Abeta amyloid peptide. An anti-Abeta amyloid antibody (AAA) was re-engineered as a fusion protein with a blood-brain barrier (BBB) molecular Trojan horse. The AAA ...

PubMed Central

169
Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside.
2010-04-01

Morbidities of aging and Alzheimer's disease (AD) have been related to defective functions of both T cells and macrophages leading to brain amyloidosis and inflammation. In AD patients, "inflammaging" may be associated with an increase of incompetent memory T cells and inflammatory cytokines produced by macrophages, whereas defective clearance of amyloid-beta 1-42 (Abeta) may ...

PubMed

170
Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats.
2010-04-02

Nicotine was reported to reduce the plaque burden and could be used as a possible anti-Alzheimer's disease agent. However, the effect of nicotine on memory and tau pathology in Alzheimer's disease has been less studied. The present study investigated the effect of nicotine on tau phosphorylation and cognitive impairment induced by hippocampus injections of amyloid-beta (Abeta) ...

PubMed

171
Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity.

As aged population dramatically increases in these decades, efforts should be made on the intervention for curing age-associated neurodegenerative diseases such as Alzheimer's disease (AD). Natural plant extracts of Lycium barbarum are well-known to exhibit anti-aging effects. We therefore hypothesized that they exhibit neuroprotective effects against toxins in aging-related neurodegenerative ...

PubMed

172
Cerebral beta-amyloid angiopathy in aged squirrel monkeys.
2007-02-01

Cerebral beta-amyloid angiopathy (CAA) is an age-related disorder of the brain vasculature that is involved in up to 20% of non-traumatic cerebral hemorrhage in humans. CAA is a risk factor for cognitive decline, and may exacerbate the dementia of Alzheimer's disease. Progress in discovering the cause and potential therapies for this disorder has been hindered by the paucity of animal models, ...

PubMed

173
Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.
2005-08-25

The abnormal accumulation of amyloid beta-peptide (Abeta) in the form of senile (or amyloid) plaques is one of the main characteristics of Alzheimer disease (AD). Both cholesterol and Cu2+ have been implicated in AD pathogenesis and plaque formation. Abeta binds Cu2+ with very high affinity, forming a redox-active complex that catalyzes H2O2 production ...

PubMed

174
Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar A? oligomers
2010-12-13

BackgroundAge-related neurodegenerative diseases share a number of important pathological features, such as accumulation of misfolded proteins as amyloid oligomers and fibrils. Recent evidence suggests that soluble amyloid oligomers and not the insoluble amyloid fibrils may represent the primary pathological species of protein aggregates.ResultsWe have ...

PubMed Central

175
Telmisartan prevented cognitive decline partly due to PPAR-{gamma} activation
2008-10-24

Telmisartan is a unique angiotensin receptor blocker (ARB) and partial agonist of peroxisome proliferator-activated receptor (PPAR)-{gamma}. Here, we investigated the preventive effect of telmisartan on cognitive decline in Alzheimer disease. In ddY mice, intracerebroventricular injection of A{beta} 1-40 significantly attenuated their cognitive function evaluated by shuttle ...

Energy Citations Database

176
Structural analysis of amyloid beta peptide fragment (25-35) in different microenvironments.
2004-01-01

Amyloid beta (Abeta) peptides are one of the classes of amphiphilic molecules that on dissolution in aqueous solvents undergo interesting conformational transitions. These conformational changes are known to be associated with their neuronal toxicity. The mechanism of structural transition involved in the monomeric Abeta to toxic assemblage is yet to be ...

PubMed

177
Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide.
2009-03-09

Our previous work in cells and animals showed that mitochondria are involved in the neuroprotective effect of huperzine A (HupA). In this study, the effects of HupA on isolated rat brain mitochondria were investigated. In addition to inhibiting the Abeta(25-35) (40 microM)-induced decrease in mitochondrial respiration, adenosine 5'-triphosphate (ATP) ...

PubMed

178
Design and biological activity of {beta}-sheet breaker peptide conjugates
2009-03-06

The sequence LPFFD (iA{beta}{sub 5}) prevents amyloid-{beta} peptide (A{beta}) fibrillogenesis and neurotoxicity, hallmarks of Alzheimer's disease (AD), as previously demonstrated. In this study iA{beta}{sub 5} was covalently linked to poly(ethylene glycol) (PEG) and the activity of conjugates was assessed and compared to the activity of the peptide alone by in vitro ...

Energy Citations Database

179
Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain.
2009-10-16

The hypothesis that amyloid-beta (Abeta) peptides are the primary cause of Alzheimer's disease (AD) remains the best supported theory of AD pathogenesis. Yet, many observations are inconsistent with the hypothesis. Abeta peptides are generated when amyloid precursor protein (APP) is cleaved by presenilins, a process that also produces APP intracellular ...

PubMed

180
Structure of murine Ia antigens. Two dimensional electrophoretic analyses and high pressure liquid chromatography tryptic peptide maps of products of the I-A and I-E subregions and of an associated invariant polypeptide
1981-04-01

We demonstrate that an invariant polypeptide, first described by Jones et al. (21), co-immunoprecipitates with our Ia molecules, that its interaction with Ia polypeptides varies with haplotype, and that it is not a precursor of the Aalpha, Abeta, Ealpha, or Ebeta. polypeptides. We also show that the polypeptides that we have previously characterized are ...

Energy Citations Database

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
181
Galanin protects against intracellular amyloid toxicity in human primary neurons.
2010-01-01

Galanin and galanin receptors are upregulated in the brain regions associated with Alzheimer's disease (AD). However, the consequence of this overexpression is still unknown, particularly in human neurons. Here, we investigate the possible protective effects of galanin against intracellular amyloid-beta (Abeta)1-42 toxicity, as well as other insults including staurosporine, ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page